astrazeneca pfizer combination :: Article CreatorAstraZeneca Adds Another Rare Disease Drug In $800M Buyout Of Startup Amolyt
Dive Brief:
AstraZeneca is bolstering its rare disease division with the purchase of Amolyt Pharma, an endocrine disease specialist backed by Novo Holdings. Under the deal announced Thursday, AstraZeneca will pay Amolyt shareholders $800 million in cash up front, with the potential for another $250 million for reaching a specific regulatory milestone. The companies expect the transaction to close in the third quarter. For AstraZeneca, the jewel of the acquisition is eneboparatide, a drug in Phase 3 testing to treat patients with hypoparathyroidism. The disease, which mostly affects women, is caused by a deficiency in parathyroid production that lowers calcium in the blood and can lead to debilitating symptoms including kidney disease. It affects about 115,000 people in the U.S. Dive Insight:
The $39 billion acquisition of Alexion three years ago instantly transformed AstraZeneca into a major player in rare diseases. Since then, the U.K. Drugmaker has been selectively picking up additional assets.
In September 2021, the company exercised an option to buy the rest of rare disease drugmaker Caelum Biosciences for $150 million. A few months later, AstraZeneca struck two deals in transthyretin amyloidosis, paying $30 million to Switzerland's Neurimmune for rights to an experimental therapy and inking a development pact with Ionis Pharmaceuticals for a drug that won approval in late 2023.
AstraZeneca is also using its foothold in rare diseases to make forays into genetic medicine, acquiring gene-editing specialist LogicBio Therapeutics and scooping up Pfizer's early gene therapy work for as much as $1 billion. And last year, the company announced plans to work with Quell Therapeutics to develop cell-based treatments for autoimmune diseases.
Amolyt has moved from a startup with preclinical assets to a Phase 3 company in less than five years. Its largest investor is Novo Holdings, the controlling shareholder of both Novo Nordisk and Novozymes. Owned by the Novo Nordisk Foundation, Novo Holdings co-led the Series A financing for Amolyt in 2019 and added to its investment with Series B and Series C funding rounds.
In addition to eneboparatide, Amolyt has an experimental drug called AZP-3813 designed as a potential treatment for acromegaly, which occurs when the body makes too much growth hormone.
Yes, You Can Donate Blood After Receiving A Covid-19 Vaccine
The American Red Cross has assured people that they can donate blood after receiving a Covid-19 ... [+] vaccine, except in rare circumstances.
getty
Recent online rumors have been circulating about whether the American Red Cross prohibits people donating blood after receiving Covid-19 vaccines. With over 80% of Americans having received at least one dose of a Covid-19 vaccine, if true, this could represent a significant danger to the U.S. Donated blood supply. The organization declared an emergency blood shortage in January, reporting that the number of blood donors had hit a 20 year low.
The good news is, the rumor isn't true.
The rumor seems to stem from this part of the eligibility criteria on the American Red Cross website about "immunization/vaccination":
COVID-19 Vaccine and COVID-19 Booster Shot Acceptable if you were vaccinated with a non-replicating, inactivated, or RNA-based COVID-19 vaccine manufactured by AstraZeneca, Janssen/J&J, Moderna, Novavax, or Pfizer providing you are symptom-free and fever-free. Wait 2 weeks if you were vaccinated with a live attenuated COVID-19 vaccine. Wait 2 weeks if you were vaccinated with a COVID-19 vaccine but do not know if it was a non-replicating, inactivated, RNA based vaccine or a live attenuated vaccine. So, in certain cases, people are being asked to wait two weeks if they were vaccinated with a certain type of Covid-19 vaccine - a live attenuated vaccine. According to the U.S. Department of Health and Human Services, a live attenuated vaccine use a weakened form of the microorganism that is responsible for disease.
For people with functional immune systems, weakened virus is not a problem and is a great stimulant of the immune response, without representing danger of the recipient getting the actual disease caused by the virus. But for people who are immunocompromised, it is possible that weakened forms of the virus can cause disease. For example, some children and adults with blood cancer often require frequent blood transfusions, but can have compromised immune systems due to their cancer and the therapies prescribed to treat it.
The large majority of Americans who have been vaccinated against Covid-19 have received the Pfizer-BioNTech or Moderna mRNA-based vaccines, or a combination of both. Some also historically received other vaccines, such as the Johnson & Johnson vaccine, which is no longer available in the U.S. And more recently in fall last year, the Novovax Covid-19 vaccine was approved for use. None of these are live-virus vaccines and no live virus vaccines are approved for widespread use in the U.S. So why is the American Red Cross asking this question?
Some trials of live Covid-19 vaccines are open in the U.S. Like this one in New York and internationally in places ranging from the U.K. To Mexico. So there is a chance, albeit very small that someone has received a live Covid-19 vaccine within 2 weeks of wanting to donate blood. Even then, these people are not prohibited from donating blood long-term, just for two weeks after the vaccine, so there is no chance of live virus existing in their blood.
There are also some trials to see whether vaccines for other viruses such as the one which causes polio might give the recipient some protection against Covid-19. Polio is often a live vaccine and the American Red Cross website also lists these and other live vaccines as reasons to delay a donation by 2-4 weeks.
The Red Cross recently released a statement clarifying eligibility to donate, stressing that most people who have received a Covid-19 vaccination can donate immediately without delay. People who have not received Covid-19 vaccines are also welcome to donate.
Global Targeted Oncology Drugs Market Set For Remarkable Growth, Expected CAGR Of 7.9% By 2030
Market Overview
The Global Targeted Oncology Drugs Market was valued at US$ 105830 million in 2022 and is projected to reach US$ 171400 million by 2030, at a CAGR of 7.9% during the forecast period.
The Targeted Oncology Drugs Market is a rapidly evolving sector within the pharmaceutical industry, driven by the increasing prevalence of cancer worldwide and the demand for more effective and personalized treatment options. Targeted Oncology Drugs Market are designed to target specific molecular pathways or proteins that are involved in the growth and spread of cancer cells. These drugs are often more selective and have fewer side effects compared to traditional chemotherapy, making them a preferred choice for many patients and healthcare providers.
The Targeted Oncology Drugs Market is segmented based on various factors, including drug type, cancer type, and mechanism of action. The market encompasses a wide range of targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies. These drugs are used to treat various types of cancer, including breast cancer, lung cancer, colorectal cancer, and melanoma, among others.
Click Here To Access Sample Pages Of This Report: http://theresearchdeck.Com/report/targeted-oncology-drugs-market/#requestForSample
Key Takeaways
The Targeted Oncology Drugs Market is witnessing significant growth due to the increasing prevalence of cancer globally. Targeted therapies offer more effective and personalized treatment options with fewer side effects. The market is segmented based on drug type, cancer type, and mechanism of action. Monoclonal antibodies, small molecule inhibitors, and immunotherapies are among the key targeted oncology drugs. The market is driven by the rising incidence of cancer and the growing awareness of personalized medicine. Research and development investments by pharmaceutical companies are fueling market growth. The approval of new targeted therapies and advanced diagnostic tools are contributing to market expansion. The Targeted Oncology Drugs Market is expected to experience substantial growth in the coming years. Regional Snapshot
The Targeted Oncology Drugs Market is characterized by diverse regional dynamics, with varying adoption rates and market penetration across different geographic regions. Here's a snapshot of the top three regions:
North America: This region is a significant contributor to the Targeted Oncology Drugs Market, driven by the high prevalence of cancer, advanced healthcare infrastructure, and the presence of leading pharmaceutical companies. The United States, in particular, has been at the forefront of targeted therapy development and adoption, with a strong focus on personalized medicine and supportive regulatory frameworks.Europe: The European Targeted Oncology Drugs Market is another major player, comprising countries with well-established healthcare systems and a high awareness of targeted therapies. Countries like Germany, the United Kingdom, France, and Italy have been actively involved in the development and commercialization of targeted oncology drugs. The region's focus on research and development, coupled with favorable reimbursement policies, has contributed to the growth of this market.Asia-Pacific: The Asia-Pacific region is emerging as a rapidly growing market for Targeted Oncology Drugs Market, fueled by the increasing incidence of cancer, improving healthcare infrastructure, and rising disposable incomes. Countries like China, Japan, and India are witnessing significant demand for targeted therapies, driven by the growing awareness of personalized medicine and the availability of advanced diagnostic tools.
Drivers
Increasing Prevalence of Cancer: The rising incidence of various types of cancer globally is a primary driver for the growth of the targeted oncology drugs market. As cancer continues to be a leading cause of mortality worldwide, there is a growing demand for more effective and targeted treatment options to improve patient outcomes. Technological Advancements in Drug Discovery: Rapid advancements in genomics, proteomics, and molecular biology have revolutionized the drug discovery process, leading to the development of more precise and targeted therapies. These technological innovations enable researchers to identify specific genetic mutations and biomarkers associated with different types of cancer, facilitating the development of tailored treatment approaches. Shift towards Personalized Medicine: There is a paradigm shift in oncology towards personalized medicine, driven by the growing understanding of the molecular mechanisms underlying cancer and the heterogeneity of tumors. Targeted oncology drugs offer the advantage of selectively targeting cancer cells based on their genetic makeup and molecular characteristics, resulting in improved efficacy and reduced side effects compared to traditional chemotherapy. This personalized approach to cancer treatment is driving the demand for targeted therapies and shaping the future of oncology care. Restraints
The Targeted Oncology Drugs Market faces several restraints that could hinder its growth. One of the primary restraints is the high cost associated with targeted therapies. The development and manufacturing processes for targeted drugs are complex and expensive, resulting in high prices that may limit accessibility, particularly in regions with limited healthcare resources or inadequate reimbursement policies.
Furthermore, the development of resistance to targeted therapies is a significant challenge. Cancer cells can adapt and develop resistance mechanisms, rendering targeted drugs ineffective over time. This necessitates the development of new therapies or combination treatments, adding to the complexity and cost of treatment.
Regulatory hurdles and stringent approval processes can also act as restraints. Regulatory agencies have strict guidelines and requirements for the approval of targeted therapies, which can prolong the development and commercialization process, potentially delaying the availability of new treatments in the market.
Enquire Here & Query for report: http://theresearchdeck.Com/report/targeted-oncology-drugs-market/#inquiry
Opportunities
The Targeted Oncology Drugs Market presents numerous opportunities for growth and innovation. One significant opportunity lies in the development of combination therapies, where targeted drugs are used in conjunction with other treatment modalities, such as chemotherapy or radiation therapy. Combining targeted therapies with other treatment approaches can potentially enhance their efficacy and overcome resistance mechanisms, leading to improved patient outcomes.
Another opportunity exists in the expansion of targeted therapies to treat rare or orphan cancers. Many rare cancers lack effective treatment options, and targeted therapies offer the potential to address these unmet medical needs, opening up new market opportunities for pharmaceutical companies.
Additionally, the integration of precision medicine and personalized healthcare approaches presents significant opportunities for the Targeted Oncology Drugs Market. By leveraging advanced diagnostic tools and data analytics, targeted therapies can be tailored to individual patients' genetic profiles and molecular characteristics, increasing the chances of successful treatment outcomes.
Challenges
The Targeted Oncology Drugs Market faces several challenges that need to be addressed. One major challenge is the development of drug resistance, as cancer cells can adapt and become resistant to targeted therapies over time. This necessitates the continuous development of new targeted drugs or combination therapies to overcome resistance mechanisms, increasing the complexity and cost of treatment.
Another challenge lies in the identification of suitable molecular targets. Not all cancer types or subtypes have well-defined molecular targets, making it difficult to develop effective targeted therapies. Extensive research and a deeper understanding of cancer biology are required to identify and validate new targets for drug development.
Toxicity and side effects are also significant challenges. While targeted therapies are generally considered to have fewer side effects compared to traditional chemotherapy, they can still cause adverse reactions in some patients. Managing these side effects and ensuring patient safety is crucial for the successful adoption and implementation of targeted therapies.
Market Segmentation
By Type
Kinase Inhibitors Monoclonal Antibodies PARP Inhibitors Other By Application
Lung Cancer Breast Cancer Prostate Cancer Blood-related Cancer Other Click Here To Access Sample Pages Of This Report: http://theresearchdeck.Com/report/targeted-oncology-drugs-market/#requestForSample
Key Players
AbbVie Johnson & Johnson Novartis Gilead Sciences Roche Bristol-Myers Squibb Amgen AstraZeneca Merck & Co Takeda Merck KGaA Seagen Eli Lilly Ono Pharmaceutical Pfizer GSK Exelixis Regeneron Innovent Hengrui Medicine Key Questions
1. What is the Targeted Oncology Drugs Market?A. The Targeted Oncology Drugs Market refers to the market for drugs that target specific molecular pathways or proteins involved in the growth and spread of cancer cells, providing more personalized and effective treatment options.
2. What are the key drivers of the Targeted Oncology Drugs Market?A. The rising incidence of cancer, advancements in molecular diagnostics, and increasing investments in research and development by pharmaceutical companies are the primary drivers of this market.
3. Which regions are leading the Targeted Oncology Drugs Market?A. North America, Europe, and the Asia-Pacific region are the major contributors to the Targeted Oncology Drugs Market, driven by factors such as advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of personalized medicine.
4. What are the challenges faced by the Targeted Oncology Drugs Market?A. Some of the key challenges include the development of drug resistance, identification of suitable molecular targets, managing toxicity and side effects, and addressing accessibility issues due to high costs and the need for advanced diagnostic tools.
5. How do targeted therapies differ from traditional chemotherapy?A. Targeted therapies are designed to target specific molecular pathways or proteins involved in cancer growth, while traditional chemotherapy drugs generally target all rapidly dividing cells, including healthy cells, leading to more side effects.
6. What opportunities exist in the Targeted Oncology Drugs Market?A. Opportunities include the development of combination therapies, expansion into rare or orphan cancers, and the integration of precision medicine and personalized healthcare approaches.
7. What will our customers gain from the Targeted Oncology Drugs Market report?A. Customers will gain valuable insights into market trends, drivers, restraints, opportunities, and challenges, as well as regional analysis and competitive landscape information, enabling them to make informed business decisions and stay ahead in this rapidly evolving market.
Top Reports:
1. Medical Diagnostic Imaging Market Set for Remarkable Growth, Expected CAGR of 7.8% by 2030: https://www.Pharmiweb.Com/press-release/2024-03-05/medical-diagnostic-imaging-market-set-for-remarkable-growth-expected-cagr-of-78-by-2030#:~:text=Drivers,is%20expected%20to%20rise%20significantly.
2. Internal Tissue Sealants Market Projected to Reach a Valuation of USD 2,754.6 Million by 2032, Reflecting Steady Growth Trends: https://www.Pharmiweb.Com/press-release/2024-03-06/internal-tissue-sealants-market-projected-to-reach-a-valuation-of-usd-2-7546-million-by-2032-refle
3. Frost Monitoring Technologies Driving Growth in the Global Frost Alarm Systems Market: https://www.Openpr.Com/news/3362709/frost-monitoring-technologies-driving-growth-in-the-global
4. Microcontroller for Automotive Market Share, Size, Trends 2024: https://www.Openpr.Com/news/3372687/microcontroller-for-automotive-market-share-size-trends-2024#:~:text=Microcontrollers%20capable%20of%20seamless%20connectivity,connected%20vehicle%20services%20and%20applications.&text=One%20of%20the%20foremost%20challenges%20is%20ensuring%20cybersecurity%20in%20connected%20vehicles.
5. Enterprise Data Integration Market Growth To Us$ 3701.9 Million By 2030 With A Cagr Of 7.5%. Discover Key Trends, Challenges, and Market Players.: https://www.Openpr.Com/news/3396144/enterprise-data-integration-market-growth-to-us-3701-9-million
Contact us:
Email: inquiry@wiredrelease.Com
Tel No: +1 (415) 315-9432
Comments
Post a Comment